Celiac Disease Bulk Plasma
Celiac Disease Bulk Plasma collected by apheresis in Acid-Citrate-Dextrose Formula A (ACDA) from IRB-consented donors with confirmed celiac disease. Tested negative for HIV, HBV and HCV. Ideal for anti-tissue transglutaminase assay development, serological reference panels and autoimmune biomarker discovery at scale.
Celiac Disease Bulk Plasma for Autoimmune and Gluten-Related Disease Research
Celiac Disease Bulk Plasma is collected from IRB-consented donors diagnosed with celiac disease using apheresis, with ACDA (Acid-Citrate-Dextrose Formula A) as the anticoagulant. Celiac disease is an autoimmune enteropathy in which dietary gluten peptides, presented in the context of HLA-DQ2 or HLA-DQ8, drive a T cell-mediated response against the small intestinal mucosa together with characteristic autoantibody production against tissue transglutaminase. This high-volume, disease-state plasma supports immunology, biomarker discovery, assay development and therapeutic discovery.
Gluten-Driven Autoimmunity and Why Bulk Plasma
- Celiac disease is genuinely autoimmune: the hallmark serological finding is IgA autoantibody against tissue transglutaminase 2 (tTG), accompanied in many patients by anti-endomysial and deamidated gliadin peptide antibodies.
- Susceptibility is tightly restricted by HLA class II. Nearly all patients carry HLA-DQ2 or HLA-DQ8, which present deamidated gluten peptides to CD4+ T cells and initiate the mucosal immune response.
- Gluten exposure and gluten-free dietary adherence directly modulate autoantibody titre, making treatment and diet status a critical variable when selecting donors.
- Bulk apheresis plasma yields the litre-scale volumes needed for antibody purification, reference and calibrator panel manufacture, and repeated-use control material — work that single-donor tubes cannot support.
- ACDA anticoagulation and apheresis collection give a consistent, high-volume matrix suited to immunoassay development and to proteomic and metabolomic discovery.
- Plasma is acellular. It supports autoantibody quantification, cytokine and mucosal damage marker immunoassay and multi-omic profiling, but not cell-based or immunophenotyping assays.
Donor Stratification Available
- Serological status: tTG-IgA positive versus normalised titre
- Gluten-free diet adherence: newly diagnosed and untreated, adherent, or non-adherent
- HLA-DQ2 or HLA-DQ8 genotype where documented
- Biopsy-confirmed diagnosis with documented histological grade where available
- Presence of associated autoimmune conditions such as type 1 diabetes or autoimmune thyroid disease
- Matched healthy controls available
Product Features
- High-volume plasma collected via apheresis
- Anticoagulated using ACDA
- Tested and confirmed negative for HIV, HBV, and HCV
- Available fresh with custom volumes upon request
- Research Use Only (RUO)
- IRB-approved informed consent and HIPAA-compliant handling
De-identified Donor Data
- Clinically confirmed diagnosis of celiac disease with diagnostic method
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Clinical history and medication data available
- Serology results and dietary status where documented
Applications
- Anti-tissue transglutaminase and deamidated gliadin peptide immunoassay development
- Serological reference, calibrator and control panel manufacture
- Autoantibody purification and characterisation at scale
- Disease-specific biomarker discovery and validation
- Cytokine and inflammatory mediator profiling
- Intestinal permeability and mucosal damage marker research
- Proteomic and metabolomic profiling of gluten-related disease
- Therapeutic development and validation studies, including gluten-degrading enzyme and immune tolerance programmes
Other Celiac Disease Specimen Types
- Celiac Disease Plasma
- Celiac Disease Serum
- Celiac Disease Whole Blood
- Celiac Disease PBMC
- Celiac Disease Leukopak
- Celiac Disease CD4+ T Cells
Compliance and Quality Assurance
- Screened negative for HIV, HBV, and HCV
- IRB-approved collection with 21 CFR Part 11–compliant consent
- Standardized processing and cryopreservation protocols
Ordering & Customization
Celiac Disease Bulk Plasma is available in standard or custom volumes. For pricing, current availability, documentation or international shipping, please contact learnmore@sanguinebio.com. To browse donor cohorts across our full inventory, visit our human plasma page.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Bulk Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.